MOH handles the supply of the vaccine so what you claim does not make sense...whether you go to a private hospital or a government hospital it would make no difference...private hospitals would not be allowed to hoard the vaccines...those in priority cats like front line and the oldies get first dibs...the rest just have to join the queue and take pot luck...Go to a high quality medical facility e.g. Gleneagles and the chances of you getting jabbed by the crappy Sinovac is lower.
If they want to hedge their bets by being kiasu and procuring three brands of vaccines, you can be kiasu and hedge bets of your own.
-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
How to avoid China's Sinovac vaccine?
- Thread starter LITTLEREDDOT
- Start date
If chinese vaccine not recognised internationally, then no use.
Government has clearly stated that the Covid vaccine will be FOC for all citizens, prs and even long term residents in Singapore...no such thing as atas and peasants in this case...only differential would be what category do you fall under with respect to health priority status I e frontline, oldies, underlying health conditions etc...
I normally inject chinese so maybe try chinese vaccine for a change.
erect, inject, eject? in that order?
no conversatioj needed. Take and die. Good tiddance
In Sinkiepore u willing to pay sure can have ur preference.
imagine being injected with tiong made fluids 
Lol. Cfm die b4 taking sinovac.
Silly man you. Sino vax is inject you with weak corona for your immune to fight. Like send invading troops with blanks. If some immune weak like Ah boy to man, even that may be also too much to handle.
Bad mouthing Chinese and China is safer, go bad mouthing Allah and Mulims if u hv balls...
motherfuckers u.
motherfuckers u.
Silly man you. Sino vax is inject you with weak corona for your immune to fight. Like send invading troops with blanks. If some immune weak like Ah boy to man, even that may be also too much to handle.
I suppose you can go clinic-/hospital hopping? Just ask what they are offering and walk away if you hear something you do not want?
So far the ang mo ones has death case but still claim 95% effective?
I think the clinic/hospital will not tell you which vaccine they are using.
Who wants to be inoculated with Sinovac's vaccine?
Brazil researchers report disappointing 50.4% efficacy for China's CoronaVac vaccine
An employee picks up a vial containing CoronaVac at a biomedical production centre in Sao Paulo, Brazil.PHOTO: REUTERS
13 JAN 2021
RIO DE JANEIRO (REUTERS) - A coronavirus vaccine developed by China’s Sinovac Biotech was just 50.4 per cent effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday (Jan 12), barely enough for regulatory approval and well below the rate announced last week.
The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world’s second-deadliest Covid-19 outbreak.
Several scientists and observers blasted the Butantan biomedical centre for releasing partial data just days ago that generated unrealistic expectations.
The confusion may add to scepticism in Brazil about the Chinese vaccine, which President Jair Bolsonaro has criticised, questioning its “origins.”
“We have a good vaccine. Not the best vaccine in the world. Not the ideal vaccine,” said microbiologist Natalia Pasternak, criticising Butantan’s triumphant tone.
Last week, the Brazilian researchers had celebrated results showing 78 per cent efficacy against “mild-to-severe” Covid-19 cases, a rate they later described as “clinical efficacy.”
They said nothing at the time about another group of “very mild” infections among those who received the vaccine that did not require clinical assistance.
Ricardo Palacios, medical director for clinical research at Butantan, said on Tuesday that the new lower efficacy finding included data on those “very mild” cases.
“We need better communicators,” said Gonzalo Vecina Neto, a professor of public health at the University of Sao Paulo and former head of Brazilian health regulator Anvisa.
Piecemeal disclosures about Chinese vaccine trials globally have raised concerns that they are not subject to the same public scrutiny as US and European alternatives.
Palacios and officials in the Sao Paulo state government, which funds Butantan, emphasised the good news that none of the volunteers inoculated with CoronaVac had to be hospitalised with Covid-19 symptoms.
Public health experts said that alone will be a relief for Brazilian hospitals that are buckling under the strain of surging case loads. However, it will take longer to curb the pandemic with a vaccine that allows so many mild cases.
“It’s a vaccine that will start the process of overcoming the pandemic,” Pasternak said.
Delays and disappointment
Researchers at Butantan delayed announcement of their results three times, blaming a confidentiality clause in a contract with Sinovac.
In the meantime, Turkish researchers said last month that CoronaVac was 91.25 per cent effective based on an interim analysis.
Indonesia gave the vaccine emergency use approval on Monday based on interim data showing it is 65 per cent effective.
Butantan officials said the design of the Brazilian study, focusing on frontline health workers during a severe outbreak in Brazil and including elderly volunteers, made it impossible to compare the results directly with other trials or vaccines.
Still, Covid-19 vaccines in use from Pfizer with partner BioNTech and Moderna proved to be about 95 per cent effective in preventing illness in their pivotal late-state trials.
The disappointing CoronaVac data is the latest setback for vaccination efforts in Brazil, where more than 200,000 people have died since the outbreak began – the worst death toll outside the United States.
Brazil’s national immunisation programme currently relies on CoronaVac and the vaccine developed by Oxford University and AstraZeneca – neither of which has received regulatory approval in Brazil.
Anvisa, which has stipulated an efficacy rate of at least 50 per cent for vaccines in the pandemic, has already pressed Butantan for more details of its study, after it filed for emergency use authorisation on Friday.
AstraZeneca failed to deliver active ingredients to Brazil over the weekend, leaving the government scrambling to import finished doses of the vaccine from India to begin inoculations.
Brazil researchers report disappointing 50.4% efficacy for China's CoronaVac vaccine
An employee picks up a vial containing CoronaVac at a biomedical production centre in Sao Paulo, Brazil.PHOTO: REUTERS
13 JAN 2021
RIO DE JANEIRO (REUTERS) - A coronavirus vaccine developed by China’s Sinovac Biotech was just 50.4 per cent effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday (Jan 12), barely enough for regulatory approval and well below the rate announced last week.
The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world’s second-deadliest Covid-19 outbreak.
Several scientists and observers blasted the Butantan biomedical centre for releasing partial data just days ago that generated unrealistic expectations.
The confusion may add to scepticism in Brazil about the Chinese vaccine, which President Jair Bolsonaro has criticised, questioning its “origins.”
“We have a good vaccine. Not the best vaccine in the world. Not the ideal vaccine,” said microbiologist Natalia Pasternak, criticising Butantan’s triumphant tone.
Last week, the Brazilian researchers had celebrated results showing 78 per cent efficacy against “mild-to-severe” Covid-19 cases, a rate they later described as “clinical efficacy.”
They said nothing at the time about another group of “very mild” infections among those who received the vaccine that did not require clinical assistance.
Ricardo Palacios, medical director for clinical research at Butantan, said on Tuesday that the new lower efficacy finding included data on those “very mild” cases.
“We need better communicators,” said Gonzalo Vecina Neto, a professor of public health at the University of Sao Paulo and former head of Brazilian health regulator Anvisa.
Piecemeal disclosures about Chinese vaccine trials globally have raised concerns that they are not subject to the same public scrutiny as US and European alternatives.
Palacios and officials in the Sao Paulo state government, which funds Butantan, emphasised the good news that none of the volunteers inoculated with CoronaVac had to be hospitalised with Covid-19 symptoms.
Public health experts said that alone will be a relief for Brazilian hospitals that are buckling under the strain of surging case loads. However, it will take longer to curb the pandemic with a vaccine that allows so many mild cases.
“It’s a vaccine that will start the process of overcoming the pandemic,” Pasternak said.
Delays and disappointment
Researchers at Butantan delayed announcement of their results three times, blaming a confidentiality clause in a contract with Sinovac.
In the meantime, Turkish researchers said last month that CoronaVac was 91.25 per cent effective based on an interim analysis.
Indonesia gave the vaccine emergency use approval on Monday based on interim data showing it is 65 per cent effective.
Butantan officials said the design of the Brazilian study, focusing on frontline health workers during a severe outbreak in Brazil and including elderly volunteers, made it impossible to compare the results directly with other trials or vaccines.
Still, Covid-19 vaccines in use from Pfizer with partner BioNTech and Moderna proved to be about 95 per cent effective in preventing illness in their pivotal late-state trials.
The disappointing CoronaVac data is the latest setback for vaccination efforts in Brazil, where more than 200,000 people have died since the outbreak began – the worst death toll outside the United States.
Brazil’s national immunisation programme currently relies on CoronaVac and the vaccine developed by Oxford University and AstraZeneca – neither of which has received regulatory approval in Brazil.
Anvisa, which has stipulated an efficacy rate of at least 50 per cent for vaccines in the pandemic, has already pressed Butantan for more details of its study, after it filed for emergency use authorisation on Friday.
AstraZeneca failed to deliver active ingredients to Brazil over the weekend, leaving the government scrambling to import finished doses of the vaccine from India to begin inoculations.
Thereis no doubt. And you cannot choose vaccine. Paying for death
Will the PAP forced Sinovac's vaccines upon the voters of Singapore?
"I'm not rejecting vaccines, I'm rejecting Sinovac's," says one Indonesian doctor, who questions its efficacy.
Wariness in Indonesia as Chinese Sinovac COVID-19 jabs start
FILE PHOTO: Officers carry COVID-19 vaccine amid the coronavirus disease (COVID-19) pandemic in Banda Aceh, Aceh Province, Indonesia, on Jan 12, 2021.
(Photo: Ampelsa/Antara Foto via REUTERS)
13 Jan 2021
JAKARTA: Indonesian doctors have suffered one of the world's highest death rates from the coronavirus, but that has not stopped some from voicing concerns over the vaccination campaign.
Nearly 1.5 million health workers are first in line to be immunised in the world's fourth most populous country after it became the first outside China to start mass vaccinations with Chinese company Sinovac Biotech's CoronaVac.
"I'm not rejecting vaccines, I'm rejecting Sinovac's," said Yusdeny Lanasakti, an East Java doctor who is worried about the vaccine's efficacy.
The vaccine was 50.4 per cent effective in a Brazilian trial, researchers said on Tuesday (Jan 12). Indonesia approved it for emergency use based on interim data showing 65.3 per cent efficacy. Turkish researchers provided an interim figure of 91.25 per cent.
Sinovac did not respond immediately to a request for comment.
Bambang Heriyanto, corporate secretary of Bio Farma, the Indonesian company involved in the trials, said the Brazilian data still topped the World Health Organization's benchmark of 50 per cent, however.
The Indonesian Medical Association, which says at least 259 Indonesian doctors died of COVID-19 by Saturday, is also encouraging use of the vaccine in the country of 270 million.
"We could reduce the high number of deaths among doctors and medical workers," said its head, Daeng M. Faqih.
Indonesian doctors' deaths amount to more than a third of India's 736 such fatalities, but India has more than five times as many people, with six times as many virus deaths as the 24,434 recorded in Indonesia from 846,765 infections.
Dominicus Husada, a pediatrician in East Java, told Reuters he was ready for vaccination but added, "There are a few aspects that have not been answered, like how long immunity lasts and how it lessens over time."
Doctors wanted more information to assuage concerns, said Tri Maharani, another East Java doctor, who has already had COVID-19 and so will not get the vaccine.
Dicky Budiman, an epidemiologist at Australia's Griffith University, added, "If there is doubt among health professionals, this means there are root issues."
These may include a strategy that is not optimal, or information supplied by the government that is not enough for professionals, particularly regarding benefits and risks, he added.
Siti Nadia Tarmizi, a senior health ministry official, said there would be no sanctions for doctors who refused vaccination, but urged medical workers not to be wary.
Most nurses are ready for vaccination, said Harif Fadhillah, who heads the Indonesian Nurses Association.
Scepticism over vaccines is an additional challenge for Indonesia in its plan to inoculate more than 180 million people living across thousands of islands over the next 15 months.
A December poll showed just 37 per cent of Indonesians were willing to be vaccinated while 40 per cent would consider it and 17 per cent refuse.
Sinovac is Indonesia's biggest vaccine supplier, but it has also secured doses from AstraZeneca and some from Pfizer and its partner BioNTech, which has shown efficacy of more than 95 per cent.
To try to spur participation in the campaign, President Joko Widodo got the Sinovac vaccine on Wednesday.
But Agnes Christie Supangkat, a doctor in Jakarta, the capital, said she was not convinced and would not be getting vaccinated.
"It seems it is being rushed to suppress the pandemic, but only a few trials have been done," she said.
"I'm not rejecting vaccines, I'm rejecting Sinovac's," says one Indonesian doctor, who questions its efficacy.
Wariness in Indonesia as Chinese Sinovac COVID-19 jabs start
FILE PHOTO: Officers carry COVID-19 vaccine amid the coronavirus disease (COVID-19) pandemic in Banda Aceh, Aceh Province, Indonesia, on Jan 12, 2021.
(Photo: Ampelsa/Antara Foto via REUTERS)
13 Jan 2021
JAKARTA: Indonesian doctors have suffered one of the world's highest death rates from the coronavirus, but that has not stopped some from voicing concerns over the vaccination campaign.
Nearly 1.5 million health workers are first in line to be immunised in the world's fourth most populous country after it became the first outside China to start mass vaccinations with Chinese company Sinovac Biotech's CoronaVac.
"I'm not rejecting vaccines, I'm rejecting Sinovac's," said Yusdeny Lanasakti, an East Java doctor who is worried about the vaccine's efficacy.
The vaccine was 50.4 per cent effective in a Brazilian trial, researchers said on Tuesday (Jan 12). Indonesia approved it for emergency use based on interim data showing 65.3 per cent efficacy. Turkish researchers provided an interim figure of 91.25 per cent.
Sinovac did not respond immediately to a request for comment.
Bambang Heriyanto, corporate secretary of Bio Farma, the Indonesian company involved in the trials, said the Brazilian data still topped the World Health Organization's benchmark of 50 per cent, however.
The Indonesian Medical Association, which says at least 259 Indonesian doctors died of COVID-19 by Saturday, is also encouraging use of the vaccine in the country of 270 million.
"We could reduce the high number of deaths among doctors and medical workers," said its head, Daeng M. Faqih.
Indonesian doctors' deaths amount to more than a third of India's 736 such fatalities, but India has more than five times as many people, with six times as many virus deaths as the 24,434 recorded in Indonesia from 846,765 infections.
Dominicus Husada, a pediatrician in East Java, told Reuters he was ready for vaccination but added, "There are a few aspects that have not been answered, like how long immunity lasts and how it lessens over time."
Doctors wanted more information to assuage concerns, said Tri Maharani, another East Java doctor, who has already had COVID-19 and so will not get the vaccine.
Dicky Budiman, an epidemiologist at Australia's Griffith University, added, "If there is doubt among health professionals, this means there are root issues."
These may include a strategy that is not optimal, or information supplied by the government that is not enough for professionals, particularly regarding benefits and risks, he added.
Siti Nadia Tarmizi, a senior health ministry official, said there would be no sanctions for doctors who refused vaccination, but urged medical workers not to be wary.
Most nurses are ready for vaccination, said Harif Fadhillah, who heads the Indonesian Nurses Association.
Scepticism over vaccines is an additional challenge for Indonesia in its plan to inoculate more than 180 million people living across thousands of islands over the next 15 months.
A December poll showed just 37 per cent of Indonesians were willing to be vaccinated while 40 per cent would consider it and 17 per cent refuse.
Sinovac is Indonesia's biggest vaccine supplier, but it has also secured doses from AstraZeneca and some from Pfizer and its partner BioNTech, which has shown efficacy of more than 95 per cent.
To try to spur participation in the campaign, President Joko Widodo got the Sinovac vaccine on Wednesday.
But Agnes Christie Supangkat, a doctor in Jakarta, the capital, said she was not convinced and would not be getting vaccinated.
"It seems it is being rushed to suppress the pandemic, but only a few trials have been done," she said.
Similar threads
